Stockholm, 2016-12-02 07:30 CET (GLOBE NEWSWIRE) -- The result of PledPharma AB’s (publ) (“PledPharma” or the “Company”) rights issue, for which the subscription period ended on 29 November 2016, indicated that 8,755,570 shares, representing approximately 43.2 percent of the offered shares, were subscribed for by exercise of subscription rights. Additionally, applications for subscription without subscription rights of 42,759 shares, corresponding to approximately 0.2 percent of the offered shares, have been received. The remaining 11,479,444 shares will be allotted to the guarantors pro rata in relation to their total undertaking, in accordance with the underwriting agreements entered into with the Company. Through the rights issue, which consequently is fully subscribed, PledPharma will receive proceeds amounting to approximately SEK 406 million before transaction related costs.
Those who have subscribed for shares without subscription rights will be allotted shares according to the principles outlined in the prospectus. Such subscribers who have been allotted shares without subscription rights are expected to be notified on 2 December 2016. Only those who are allotted shares will be notified.
Through the rights issue PledPharma’s share capital increases by approximately SEK 1,067,252 from SEK 1,494,152 to SEK 2,561,404 and the total number of shares increases by 20,277,773 from 28,388,883 to 48,666,656 when the rights issue is registered by the Swedish Companies Registration Office.
The final day for trading in paid subscribed shares (BTAs) was 1 December 2016. The new shares subscribed for with subscription rights are expected to start trading on Nasdaq Stockholm on 7 December 2016, and the shares subscribed for without subscription rights on 15 December 2016.
For further information, please contact:
Jacques Näsström, CEO, +46 73 713 09 79
Michaela Gertz, CFO, phone: +46 709 26 17 75
For more information about the Company, please visit www.pledpharma.se
Stockholm, 2 December 2016 PledPharma AB (publ)
The information in this press release is such that PledPharma AB (publ) must disclose in accordance with Market Abuse Act. The information was provided through GlobeNewswire for publication on 2 December 2016 at 07.30 CET
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an invitation or offer from PledPharma AB (publ) (”PledPharma”), Carnegie Investment Bank AB (publ) or any other person to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in PledPharma AB. An invitation to relevant persons to subscribe for shares in PledPharma will only be made through the prospectus that PledPharma intends to publish on its website when such prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus will contain, among other things, information on risk factors associated with the company’s business or the securities referred to in this press release, financial statements as well as information regarding the company’s board of directors. This press release has not been approved by any regulatory authority and does not constitute a prospectus. Investors should not subscribe for or purchase any securities referred to in this press release, unless such investment decision is based on the information contained in the prospectus that will be published by PledPharma.
The information in this press release is not intended to be, and may not be, announced, published or distributed, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zeeland, Singapore, South Africa or any other country where such action would be illegal or is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, other offer documentation, registrations or other actions in addition to what follows from Swedish law. The recipient of this press release is responsible for that the recipient’s use of this press release and the information contained herein is in accordance with applicable laws in any relevant jurisdictions.
If and to the extent that this press release is communicated in any European Economic Area (EEA) member state that has implemented Directive 2003/71/EC in its current wording (together with any applicable implementing measures in such member state, the "Prospectus Directive"), this press release is only addressed to and directed at persons in such EEA member state who meet the criteria for an exemption from the obligation to draw up and publish a prospectus as implemented in such member state, such as for example qualified investors as defined in the Prospectus Directive.
This press release does not, and will not, contain or constitute an invitation or offer to acquire or subscribe for securities in the United States. The securities referred to in this press release may not be offered or sold in the United States without registration or an exemption from registration in accordance with the United States Securities Act of 1933 in its current wording (“Securities Act”). PledPharma does not intend to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.
This press release, and any other material concerning the securities referred to herein, is only being distributed to and directed at (i) persons outside the United Kingdom and Northern Ireland (ii) persons with professional experience in matters relating to investments who fall within the scope of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order"), or (iii) high net worth companies and other persons to whom this press release may otherwise be lawfully communicated pursuant to Article 49(2)(a) to (d) of the Financial Promotion Order. All persons in (i) – (iii) above are together being referred to as "relevant persons". The securities referred to in this press release are only available to relevant persons, and any invitation, offer or agreement regarding the subscription or acquisition of such securities is directed exclusively at such relevant persons. A person who is not a relevant person may not act on or rely upon this press release or the information contained herein.
